U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Apple Turns 50: From Garage Startup to AI Crossroads 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
LOS ANGELES, June 26, 2017 -- Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular” or the “Company”) (NYSE MKT:IMUC) regarding possible violations of federal securities laws from May 1, 2012 through December 11, 2013, inclusive (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the firm prior to the June 30, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here.
You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at [email protected].
No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may do nothing and be an absent class member as well.
According to the Complaint, during the Class Period, ImmunoCellular issued materially false and/or misleading statements, and/or failed to disclose that ImmunoCellular retained Lidingo Holdings, LLC to publish articles designed to unlawfully promote the Company; and that as a result of this scheme, the market was led to believe that the Company’s clinical studies for its product candidate (ICT-107) was going well and the share price was artificially inflated. Following this news, the Company’s stock price dropped materially, which harmed investors according to the Complaint. On April 10, 2017, the Securities & Exchange Commission announced enforcement actions against numerous individuals and entities, including ImmunoCellular, which engaged in stock promotion schemes.
Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles devoted to upholding shareholders’ rights.
This press release may constitute Attorney Advertising in certain jurisdictions under the applicable law and ethics rules.
Contact: Lundin Law PC Brian Lundin, Esq. Telephone: 888-713-1033 Facsimile: 888-713-1125 [email protected] http://lundinlawpc.com/
